share_log

Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why

Benzinga ·  Dec 11, 2023 22:05

Pasithea Therapeutics Corp (NASDAQ:KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation cancer xenograft models.

In the first study, PAS-004 exhibited dose-dependent antitumor efficacy in the lung cancer NCI-H1299 cell-line-derived xenograft model. PAS-004 at dose levels of 10 mg/kg and 5 mg/kg, once daily, significantly inhibited tumor growth compared to vehicle control.

The antitumor efficacy of PAS-004, when taken at equivalent doses, was shown to be superior to that of Pfizer Inc's (NYSE:PFE) Mektovi (binimetinib) and AstraZeneca Plc's (NASDAQ:AZN) Koselugo (selumetinib).

In the second study, PAS-004 exhibited dose-dependent antitumor efficacy in the liver cancer xHepG2 cell-line-derived xenograft model. PAS-004 at dose levels of 10 mg/kg and 5 mg/kg, once daily, produced significant antitumor activities compared to vehicle control.

The antitumor efficacy of PAS-004, when taken at equivalent doses, was shown to be similar to that of binimetinib and superior to that of selumetinib.

The company plans to start the Phase 1 study as early as the first quarter of 2024, following acceptance of the company's Investigational New Drug Application (IND) with the FDA.

Price Action: KTTA shares are up 172.90% at $0.82 during the premarket session on the last check Monday.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment